PEPGEN INC (PEPG)
US7133171055 - Common Stock
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
Stay updated with the stocks that are on the move in Friday's pre-market session.
PepGen to Participate in Upcoming Investor Conferences
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
PEPG stock results show that PepGen beat analyst estimates for earnings per share the fourth quarter of 2023.
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PepGen (NASDAQ:PEPG) just reported results for the fourth quarter of 2023.PepGe...
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary...
PepGen announces pricing of $80.1M underwritten offering (NASDAQ:PEPG)
PepGen Inc. (PEPG) has priced its underwritten offering, expecting to raise approximately $80.1 million through the sale of its common stock.
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PepGen stock soars after rival Sarepta reports data for DMD drug (NASDAQ:PEPG)
PepGen (PEPG) stock soared 44% Tuesday, the day after rival Sarepta (SRPT) released data of its drug SRP-5051 in the treatment of Duchenne muscular dystrophy. Read more here.
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- Continuing to open CONNECT1-EDO51 trial sites in Canada - - Opening of FREEDOM-DM1 trial sites underway in the U.S. and Canada - -...
FDA lifts clinical hold on US Phase 1 study for DM1 drug candidate (PEPG)
The FDA lifted a clinical hold on a US Phase 1 clinical trial for PegGen's drug candidate to treat myotonic dystrophy type 1, or DM1.
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg – – Safety, transcript...
PepGen is Now Oversold (PEPG)
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1)
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide - - EDO technology...